Published in Basic Appl Histochem on January 01, 1983
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol (1998) 3.65
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol (1997) 1.85
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol (1987) 1.68
Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett (1988) 1.61
Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer (2001) 1.60
Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci (1987) 1.60
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer (1994) 1.51
Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column. A simple procedure for the purification of fibronectin domains. Eur J Biochem (1985) 1.51
Expression of emmprin by oral squamous cell carcinoma. Int J Cancer (2000) 1.42
Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol (1986) 1.37
Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies. J Biol Chem (1985) 1.34
Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res (1991) 1.31
Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett (1990) 1.28
Fibronectin: a chromatin-associated protein? Cell (1979) 1.25
Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. coli. FEBS Lett (1987) 1.24
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1994) 1.23
Fetal myofibroblast-like cells isolated from post-radiation fibrosis in human breast cancer. Int J Cancer (1991) 1.22
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res (2001) 1.21
Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem (1996) 1.19
Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem (1995) 1.19
A high-affinity human antibody that targets tumoral blood vessels. Blood (1999) 1.16
Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol (1987) 1.16
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer (1991) 1.16
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol (2002) 1.15
Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest (1995) 1.14
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res (1999) 1.14
A simplified procedure for the preparation of antibodies to serum fibronectin. J Immunol Methods (1980) 1.13
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer (1996) 1.12
Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer (1999) 1.12
Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1992) 1.11
Large-scale procedure for the purification of fibronectin domains. Anal Biochem (1986) 1.11
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol (1999) 1.10
Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum (1994) 1.10
Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4beta1 and alpha4beta7 integrins. J Biol Chem (1997) 1.08
The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem (1995) 1.07
The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem (1992) 1.07
Monoclonal antibodies in analysis of cathepsin G-digested proteolytic fragments of human plasma fibronectin. J Immunol Methods (1982) 1.06
Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol (1999) 1.05
Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res (1999) 1.04
Binding of tenascin-C to soluble fibronectin and matrix fibrils. J Biol Chem (1995) 1.03
Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett (1993) 1.02
Tenascin and fibronectin distribution in human normal and pathological synovium. J Rheumatol (1992) 1.02
Somatic cell hybrids producing antibodies specific to human fibronectin. Int J Cancer (1980) 1.01
Characterization of synovial fluid fibronectin from patients with rheumatic inflammatory diseases and healthy subjects. Arthritis Rheum (1984) 1.01
Changes in polyamine metabolism in WI38 cells stimulated to proliferate. Exp Cell Res (1975) 1.00
Primary structure of a DNA- and heparin-binding domain (Domain III) in human plasma fibronectin. J Biol Chem (1985) 0.99
Biological effects of a neurotoxic pesticide at low concentrations on sea urchin early development. A terathogenic assay. Chemosphere (1998) 0.97
Can heterologous collagen enhance the granulation tissue growth? An experimental study. Ital J Surg Sci (1983) 0.97
Human mitochondrial DNA. J Mol Biol (1968) 0.96
Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer (1997) 0.95
Modulation of matrix adhesive responses of human neuroblastoma cells by neighboring sequences in the fibronectins. J Cell Biol (1988) 0.95
Demonstration of structural differences between the two subunits of human-plasma fibronectin in the carboxy-terminal heparin-binding domain. Eur J Biochem (1987) 0.94
Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab Invest (1998) 0.94
Immunospecificity to non-histone chromosomal proteins of anti-chromatin antibodies. Nat New Biol (1973) 0.94
TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J (1995) 0.93
High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig (2006) 0.92
Tenascin distribution in human brain tumours. Acta Neurochir (Wien) (1995) 0.92
Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int (2003) 0.91
Species-specific monoclonal antibodies in the assignment of the gene for human fibronectin to chromosome 2. EMBO J (1982) 0.91
Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer (1990) 0.91
Interaction between organophosphate compounds and cholinergic functions during development. Chem Biol Interact (2005) 0.90
Presence of ED-A containing fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis. J Rheumatol (1996) 0.90
Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J (1989) 0.90
DNA-binding domains of human plasma fibronectin. pH and calcium ion modulation of fibronectin binding to DNA and heparin. Eur J Biochem (1986) 0.89
Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer (1998) 0.89
Chicken antichromatin antibodies: specificity to different chromatin fractions. Eur J Biochem (1975) 0.89
Human tenascin gene. Structure of the 5'-region, identification, and characterization of the transcription regulatory sequences. J Biol Chem (1995) 0.89
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med (2001) 0.88
High-resolution cryo-scanning electron microscopy study of the macromolecular structure of fibronectin fibrils. Scanning (1997) 0.88
Elution of human satellite DNAs on a methylated albumin kieselguhr chromatographic column: isolation of satellite DNA. IV. Biochim Biophys Acta (1972) 0.88
Concentration of fibronectin in plasma of tumor-bearing mice and synthesis by Ehrlich ascites tumor cells. Cancer Res (1979) 0.88
Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun (1994) 0.88
Biological targets of neurotoxic pesticides analysed by alteration of developmental events in the Mediterranean sea urchin, Paracentrotus lividus. Mar Environ Res (2003) 0.87
Expression of EDA+ and EDB+ fibronectin splice variants in bone. Bone (2004) 0.86
Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastasis (1999) 0.86
Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer (1996) 0.86
A functional monoclonal antibody recognizing the human alpha 1-integrin I-domain. Tissue Antigens (1996) 0.86
Stromal fibroblasts influence oral squamous-cell carcinoma cell interactions with tenascin-C. Int J Cancer (1997) 0.85
Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren). Histochem Cell Biol (1998) 0.85
Conformational state of circulating human plasma fibronectin. FEBS Lett (1984) 0.85